Zusammenfassung
Traditionell galt das Urothelkarzinom des oberen Harntrakts (OHT) als klare Indikation zur radikalen Nephroureterektomie mit Blasenmanschettenresektion. Bei gut selektionierten Patienten und abhängig vom Tumorstadium zeigt sich jedoch, dass eine nierenerhaltende Therapie onkologisch zu ähnlich guten Ergebnissen wie eine Nephroureterektomie führen kann. Eine wichtige Rolle in der nierenerhaltenden Therapie nimmt nebst der lokalen Tumortherapie mittels ablativer ureteroskopischer Verfahren (u. a. Laserverfahren) das Verhindern von Rezidiven lokal wie auch in der Blase ein. Instillationstherapien des OHT mit Bacillus Calmette-Guérin und/oder Mitomycin C haben diesbezüglich Erfolge erzielt. Die Datenlage ist jedoch aufgrund der Seltenheit der Erkrankung sowie der meist retrospektiven Studien eingeschränkt. Im Folgenden geben wir einen Überblick über die Indikationen, die technische Durchführung und die Resultate der Instillationstherapie des OHT.
Abstract
Traditionally, urothelial carcinoma of the upper urinary tract was a clear indication for radical nephroureterectomy with bladder cuff excision. It has been shown that in well-selected patients and depending on tumor stage, a kidney-sparing approach can be pursued with good oncological outcome and equivalent to the radical approach. The prevention of local and bladder recurrences is an important factor. Instillation therapies with bacillus Calmette-Guérin and/or mitomycin C have been successfully used to this end. Due to the low incidence of upper tract urothelial cancer and due to the usually retrospective nature of existing literature, however, data is limited. In this article, we provide a review of the indication, technical execution and results of instillation therapies of the upper urinary tract.
Literatur
Aboumarzouk OM, Somani B, Ahmad S et al (2013) Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma. Urol Ann 5:184–189
Chade DC, Shariat SF, Godoy G et al (2010) Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol 184:74–80
Chen GL, Bagley DH (2000) Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. J Urol 164:1173–1176
Cutress ML, Stewart GD, Wells-Cole S et al (2012) Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int 110:1608–1617
Cutress ML, Stewart GD, Zakikhani P et al (2012) Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int 110:614–628
Daneshmand S, Quek ML, Huffman JL (2003) Endoscopic management of upper urinary tract transitional cell carcinoma: long-term experience. Cancer 98:55–60
European Association of Urology Guidelines (2018) EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS) 2018. In: 2018 edition. European Association of Urology Guidelines Office, Arnhem
Fang D, Li XS, Xiong GY et al (2013) Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis. Urol Int 91:291–296
Gadzinski AJ, Roberts WW, Faerber GJ et al (2010) Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol 183:2148–2153
Giannarini G, Kessler TM, Birkhauser FD et al (2011) Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol 60:955–960
Grasso M, Fraiman M, Levine M (1999) Ureteropyeloscopic diagnosis and treatment of upper urinary tract urothelial malignancies. Urology 54:240–246
Herr HW (1985) Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette-Guerin. J Urol 134:531–532
Horiguchi H, Yoneyama T, Hatakeyama S et al (2018) Impact of bacillus Calmette-Guerin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy. Med Oncol 35:41
Huang WC, Levey AS, Serio AM et al (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7:735–740
Irie A, Iwamura M, Kadowaki K et al (2002) Intravesical instillation of bacille Calmette-Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology 59:53–57
Jarrett TW, Sweetser PM, Weiss GH et al (1995) Percutaneous management of transitional cell carcinoma of the renal collecting system: 9‑year experience. J Urol 154:1629–1635
Krabbe LM, Lotan Y, Bagrodia A et al (2014) Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract—is there evidence for discordant biology? J Urol 191:926–931
Martinez-Pineiro JA, Garcia Matres MJ, Martinez-Pineiro L (1996) Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol 156:377–385
Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116:180–183
Nunez-Nateras R, Castle EP, Protheroe CA et al (2014) Predicting response to bacillus Calmette-Guerin (BCG) in patients with carcinoma in situ of the bladder. Urol Oncol 32:45e23–45e30
Pettenati C, Ingersoll MA (2018) Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol 15(10):615
Pollard ME, Levinson AW, Shapiro EY et al (2013) Comparison of 3 upper tract anticarcinogenic agent delivery techniques in an ex vivo porcine model. Urology 82:1451.e1–1451.e6
Raymundo EM, Lipkin ME, Banez LB et al (2011) Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma. J Endourol 25:377–384
Rouprêt M, Babjuk M, Burger M et al (2018) EAU guidelines on upper urinary tract urothelial carcinoma 2018. In: European Association of Urology (Hrsg) 2018 edition. European Association of Urology Guidelines Office, Arnhem
Roupret M, Hupertan V, Traxer O et al (2006) Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology 67:1181–1187
Sfakianos JP, Cha EK, Iyer G et al (2015) Genomic characterization of upper tract urothelial carcinoma. Eur Urol 68:970–977
Sorokin I, Welliver RC Jr., Elkadi O et al (2013) Tumor seeding of percutaneous nephrostomy tract from urothelial carcinoma of the kidney. Case Rep Urol 2013:819470
Thalmann GN, Markwalder R, Walter B et al (2002) Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol 168:1381–1385
Thompson RH, Krambeck AE, Lohse CM et al (2008) Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. Urology 71:713–717
Xylinas E, Rink M, Margulis V et al (2013) Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int 112:453–461
Yakoubi R, Colin P, Seisen T et al (2014) Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: a meta-analysis and a systematic review of current evidence from comparative studies. Eur J Surg Oncol 40:1629–1634
Zhang Z, Furge KA, Yang XJ et al (2010) Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. BMC Med Genomics 3:58
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
P. Bosshard, G.N. Thalmann und B. Roth geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Bosshard, P., Thalmann, G.N. & Roth, B. Instillationstherapien beim Urothelkarzinom des oberen Harntraktes. Urologe 58, 25–29 (2019). https://doi.org/10.1007/s00120-018-0830-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-018-0830-0